Talk:Biological response modifier

This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:

Medicine Mid‑importance This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine. Mid This article has been rated as Mid-importance on the project's importance scale. Pharmacology Mid‑importance This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks. Mid This article has been rated as Mid-importance on the project's importance scale.

The content of Biologics for immunosuppression was merged into Biological response modifier on 10 November 2023. The former page's history now serves to provide attribution for that content in the latter page, and it must not be deleted as long as the latter page exists. For the discussion at that ___location, see its talk page.

Improve intro and structure

Latest comment: 15 years ago1 comment1 person in discussion

[1] seems to have a better overview.

We could group them by target (eg TNF-a).

Actemra/tocilizumab (an anti-IL6) is also considered a BRM. Rod57 (talk) 16:17, 9 March 2010 (UTC)Reply